Literature DB >> 26302933

HBD-3 induces NK cell activation, IFN-γ secretion and mDC dependent cytolytic function.

Chelsey J Judge1, Elane Reyes-Aviles2, Sara J Conry3, Scott S Sieg3, Zhimin Feng4, Aaron Weinberg4, Donald D Anthony5.   

Abstract

We previously showed that human beta defensin-3 (hBD-3) activates mDC via TLR1/2. Here we investigated the effects of hBD-3 on NK cell activation state and effector functions. We observed that hBD-3 activates PBMC to secrete IFN-γ and kill K562 and HUH hepatoma target cells in an NK dependent fashion, and both TLR1/2 and CCR2 are involved. TLR1, TLR2 and CCR2 were expressed on NK cells, and in purified NK culture experiments we observed hBD-3 to directly act on NK cells, resulting in CD69 upregulation and IFNγ secretion. We also observed mDC-hBD-3 enhanced NK cytolytic activity and IFNγ production. These results implicate hBD-3 in its ability to directly activate NK cells and increase NK cell effector function, as well as promote mDC-dependent NK activity. HBD-3 may therefore act as a mediator of innate cell interactions that result in bridging of innate and adaptive immunity. Published by Elsevier Inc.

Entities:  

Keywords:  Defensin; Dendritic cell; Human; Immunity; Innate; Natural killer cell

Mesh:

Substances:

Year:  2015        PMID: 26302933      PMCID: PMC4682877          DOI: 10.1016/j.cellimm.2015.06.004

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  36 in total

Review 1.  Toll like receptors and viruses.

Authors:  Robert W Finberg; Jennifer P Wang; Evelyn A Kurt-Jones
Journal:  Rev Med Virol       Date:  2007 Jan-Feb       Impact factor: 6.989

2.  Variable requirement of dendritic cells for recruitment of NK and T cells to different TLR agonists.

Authors:  Takefumi Uchida; Philip O Scumpia; Donna M Murasko; Shuhji Seki; Susan Woulfe; Michael J Clare-Salzler; Lyle L Moldawer
Journal:  J Immunol       Date:  2007-03-15       Impact factor: 5.422

Review 3.  NK cells and immune "memory".

Authors:  Joseph C Sun; Sandra Lopez-Verges; Charles C Kim; Joseph L DeRisi; Lewis L Lanier
Journal:  J Immunol       Date:  2011-02-15       Impact factor: 5.422

Review 4.  NK cells at the interface between innate and adaptive immunity.

Authors:  A Moretta; E Marcenaro; S Parolini; G Ferlazzo; L Moretta
Journal:  Cell Death Differ       Date:  2007-06-01       Impact factor: 15.828

5.  Human beta-defensin 2 and 3 and their mouse orthologs induce chemotaxis through interaction with CCR2.

Authors:  Johann Röhrl; De Yang; Joost J Oppenheim; Thomas Hehlgans
Journal:  J Immunol       Date:  2010-05-17       Impact factor: 5.422

6.  TLR ligand-dependent activation of naive CD4 T cells by plasmacytoid dendritic cells is impaired in hepatitis C virus infection.

Authors:  Nicole L Yonkers; Benigno Rodriguez; Kimberly A Milkovich; Robert Asaad; Michael M Lederman; Peter S Heeger; Donald D Anthony
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

7.  The Toll-like receptor 1/2 agonists Pam(3) CSK(4) and human β-defensin-3 differentially induce interleukin-10 and nuclear factor-κB signalling patterns in human monocytes.

Authors:  Nicholas T Funderburg; Julie K Jadlowsky; Michael M Lederman; Zhimin Feng; Aaron Weinberg; Scott F Sieg
Journal:  Immunology       Date:  2011-10       Impact factor: 7.397

8.  Interferon-gamma secretion is induced in IL-12 stimulated human NK cells by recognition of Helicobacter pylori or TLR2 ligands.

Authors:  Asa Lindgren; Voja Pavlovic; Carl-Fredrik Flach; Asa Sjöling; Samuel Lundin
Journal:  Innate Immun       Date:  2010-02-03       Impact factor: 2.680

9.  Human -defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2.

Authors:  Nicholas Funderburg; Michael M Lederman; Zhimin Feng; Michael G Drage; Julie Jadlowsky; Clifford V Harding; Aaron Weinberg; Scott F Sieg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-15       Impact factor: 11.205

10.  Systemic immune activation in HIV infection is associated with decreased MDC responsiveness to TLR ligand and inability to activate naive CD4 T-cells.

Authors:  Nicole L Yonkers; Benigno Rodriguez; Robert Asaad; Michael M Lederman; Donald D Anthony
Journal:  PLoS One       Date:  2011-09-01       Impact factor: 3.240

View more
  6 in total

1.  Identification of compound-protein interactions through the analysis of gene ontology, KEGG enrichment for proteins and molecular fragments of compounds.

Authors:  Lei Chen; Yu-Hang Zhang; Mingyue Zheng; Tao Huang; Yu-Dong Cai
Journal:  Mol Genet Genomics       Date:  2016-08-16       Impact factor: 3.291

2.  Overexpressing ovotransferrin and avian β-defensin-3 improves antimicrobial capacity of chickens and poultry products.

Authors:  Caitlin A Cooper; Mark L Tizard; Tamsyn Stanborough; Sean C Moore; P Scott Chandry; Kristie A Jenkins; Terry G Wise; Terri E O'Neil; Daniel S Layton; Kirsten R Morris; Robert J Moore; Narelle Fegan; Timothy J Doran
Journal:  Transgenic Res       Date:  2018-10-29       Impact factor: 2.788

Review 3.  The Dichotomous Responses Driven by β-Defensins.

Authors:  Jennifer R Shelley; Donald J Davidson; Julia R Dorin
Journal:  Front Immunol       Date:  2020-06-12       Impact factor: 7.561

4.  Design an Efficient Multi-Epitope Peptide Vaccine Candidate Against SARS-CoV-2: An in silico Analysis.

Authors:  Zahra Yazdani; Alireza Rafiei; Mohammadreza Yazdani; Reza Valadan
Journal:  Infect Drug Resist       Date:  2020-08-25       Impact factor: 4.003

5.  Designing a multi-epitope vaccine to provoke the robust immune response against influenza A H7N9.

Authors:  Hossein Tarrahimofrad; Somayyeh Rahimnahal; Javad Zamani; Ehsan Jahangirian; Saeed Aminzadeh
Journal:  Sci Rep       Date:  2021-12-29       Impact factor: 4.379

6.  Human β-Defensin-3 is Associated With Platelet-Derived Extracellular Vesicles and is a Potential Contributor to Endothelial Dysfunction.

Authors:  Soumya Panigrahi; Santosh K Ghosh; Brian Ferrari; Jonathan M Wyrick; Eugene A Podrez; Aaron Weinberg; Scott F Sieg
Journal:  Front Mol Biosci       Date:  2022-03-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.